发明授权
US06890922B2 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
有权
2-苯基取代的咪唑并三嗪酮作为磷酸二酯酶抑制剂
- 专利标题： 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
- 专利标题（中）： 2-苯基取代的咪唑并三嗪酮作为磷酸二酯酶抑制剂
-
申请号： US10365740申请日： 2003-02-12
-
公开(公告)号： US06890922B2公开(公告)日： 2005-05-10
- 发明人: Ulrich Niewöhner
- 申请人： Maria Niewohner , Mazen Es-Sayed , Helmut Haning , Thomas Schenke , Karl-Heinz Schlemmer , Jörg Keldenich , Erwin Bischoff , Elisabeth Perzborn , Klaus Dembowsky , Peter Serno , Marc Nowakowski
- 申请人地址： DE Leverkusen
- 专利权人： Bayer Healthcare AG
- 当前专利权人： Bayer Healthcare AG
- 当前专利权人地址： DE Leverkusen
- 代理商 Susan M. Pellegrino
- 优先权： DE19750085 19971112; DE19812462 19980323; DE19840289 19980904
- 主分类号： A61K31/00
- IPC分类号： A61K31/00 ; A61K31/53 ; A61K31/5375 ; A61K31/5377 ; A61K31/541 ; A61K31/55 ; A61K31/551 ; A61K31/662 ; A61P9/00 ; A61P9/10 ; A61P11/08 ; A61P13/02 ; A61P13/08 ; A61P13/10 ; A61P15/00 ; A61P15/10 ; A61P43/00 ; C07D20060101 ; C07D487/04 ; C07D491/113 ; C07D519/00 ; C07F9/6561
摘要：
The 2-phenyl-substituted imidazotriazinones having short, unbranched alkyl radicals in the 9-position are prepared from the corresponding 2-phenyl-imidazotriazinones by chlorosulphonation and subsequent reaction with the amines. The compounds inhibit cGMP-metabolizing phosphodiesterases and are suitable for use as active compounds in pharmaceuticals, for the treatment of cardiovascular and cerebrovascular disorders and/or disorders of the urogenital system, in particular for the treatment of erectile dysfunction.
公开/授权文献
信息查询
